Leukemia treatment is advancing rapidly with targeted therapies and immunotherapies that offer more precise and less toxic alternatives to traditional chemotherapy. A breakthrough in 2025 is the development of menin inhibitors, which block the interaction between menin and KMT2A proteins critical for leukemia cell survival. Revumenib, approved by the FDA, has shown high remission rates in treatment-resistant KMT2A-rearranged leukemia and is taken orally at home. Another menin inhibitor, Ziftomenib, has demonstrated durable responses in AML patients with NPM1 mutations. Combination therapies, such as pairing MCL-1 inhibitors with SRC inhibitors, are being explored to overcome resistance and prevent relapse.
Immunotherapy is also evolving. CAR T-cell therapies are being refined, including “off-the-shelf” allogeneic versions for faster treatment. Combinations with drugs like Blinatumomab have reduced recurrence in acute lymphoblastic leukemia. Next-generation CAR designs enhance persistence and anti-tumor activity via pathways like JAK/STAT.
Novel targets, such as the PSPC1 protein and leukemia microenvironment pathways, offer additional avenues for future therapies, aiming to destroy leukemia stem cells while sparing healthy tissue.